Van de Veire, S;
Van de Veire, S;
Van Steenkiste, C;
De Mol, M;
Van Bergen, T;
Le Henaff, C;
Van Vlierberghe, H;
- view fewer
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.
178 - 190.
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
|Title:||Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease|
|Keywords:||PLACENTA GROWTH-FACTOR, HEPATOCELLULAR-CARCINOMA, PATHOLOGICAL CONDITIONS, MOUSE MODEL, METASTASIS, ANGIOGENESIS, MICE, PROGRESSION, HYPOXIA, LUNG|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Medical Sciences
Archive Staff Only